

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU4591	SERIAL NO. 10/506,647
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Jodi Marie MAGLICH et al.	
		FILING DATE September 3, 2004	GROUP 1847

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

SHS	1	MAGLICH J M ET AL; The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction; J. BIOL. CHEM.; 7 MAY 2004; VOL 279 No. 19; 19832-19838;
↓	2	QATANANI M ET AL; Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism; ENDOCRINOL; 24 November 2004; 146, no. 3; 995-1002;
↓	3	UEDA A ET AL; Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital; MOL. PHARMACOL; 1 January 2002; 61, no. 1; 1-8;

Examiner Signature Shulamith H. Shafer	<small>Digitally signed by Shulamith H. Shafer DN: cn=Shulamith H. Shafer, o=US e=shulamith.shafer@uspto.gov Date: 2007.02.22 12:25:53 -0500</small>	Date Considered 02/22/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4591USw		SERIAL NO. 06 647	
				APPLICANT Jodi Marie MAGLICH et al.			
				FILING DATE Concurrently herewith		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
SHS	1.	WO 01/51045	07/19/2001	WIPO			
SHS	2.	WO 02/25134	03/28/2002	WIPO			X (Abstract)
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	3.	Choi et al., "Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR," <i>Journal Biological Chemistry</i> 272(38):23565-23571 (Sep. 1997).					
	4.	Moore et al., "Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic steroid ligands," <i>Journal Biological Chemistry</i> 275(20):15122-15127 (May 2000).					
	5.	Suayochi et al., "The repressed nuclear receptor CAR responds to Phenobarbital in activating the human CYP2B6 gene," <i>Journal Biological Chemistry</i> 274(10):6043-6046 (Mar. 1999).					
	6.	Wei et al., "The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism," <i>Nature</i> 407:920-923 (Oct. 2000).					
SHS	7.	Barter et al., "UDP-glucuronosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism," <i>Toxicol. Appl. Pharmacol.</i> 113:36-42 (1992).					
	8.	Berti et al., "Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice," <i>Metabolism</i> 50(5):530-536 (May 2001).					
	9.	Burchell et al., "UDP Glucuronosyltransferases," <i>Pharmacol. Ther.</i> 43(2):261-289 (1989).					
	10.	Diwan et al., "Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene in rats at doses that cause maximal induction of CYP2B," <i>Carcinogenesis</i> 17(1):37-43 (Jan. 1996).					
	11.	Feng et al., "Thyroid hormone regulation of hepatic genes <i>in vivo</i> detected by complementary DNA microarray," <i>Mol. Endocrinol.</i> 14(7):947-955 (Jul. 2000).					
	12.	Fields et al., "A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340(6230):245-246 (Jul. 1989).					
	13.	Honkakoski et al., "The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the Phenobarbital-responsive enhancer module of the CYP2B gene," <i>Mol. Cell. Biol.</i> 18(10):5652-5658 (Oct. 1998).					
	14.	Hulsmann et al., "Effect of hypothyroidism, diabetes and polyunsaturated fatty acids on heparin-releasable rat liver lipase," <i>Biochem. Biophys. Res. Commun.</i> 79(3):784-788 (1977).					
	15.	Iossa et al., "Fat balance and serum leptin concentrations in normal, hypothyroid, and hyperthyroid rats," <i>International Journal of Obesity</i> 25(3):417-425 (Feb. 2001).					
✓	16.	Keppler et al., "Hepatic secretion of conjugated drugs and endogenous substances," <i>Seminars in Liver Disease</i> 20(3):265-272 (2000).					
Continue on page 2							
EXAMINER						DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4591USw		SERIAL NO. To Be Assigned 506647	
				APPLICANT Jodi Marie MAGLICH et al.			
				FILING DATE Concurrently herewith		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) (Cont'd)							
SHS	17.	Kolaja et al., "Dose-response examination of UDP-glucuronosyltransferase inducers and their ability to increase both TGF- β expression and thyroid follicular cell apoptosis," <i>Toxicol. Sci.</i> 46(1) :31-37 (Nov. 1998).					
	18.	Lavery et al., "Circadian expression of the steroid 15 α -hydroxylase (<i>Cyp2a4</i>) and coumarin 7-hydroxylase (<i>Cyp2a5</i>) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP," <i>Mol. Cell Biol.</i> 19(10) :6488-6499 (Oct. 1999).					
	19.	Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferators-activated receptor γ ligand binding domain," <i>Anal. Biochem.</i> 257(2) :112-119 (Mar. 1998).					
	20.	Parks, "Bile acids: natural ligands for an orphan nuclear receptor," <i>Science</i> 284(5418) :1365-1368 (May 1999).					
	21.	Ridgway et al., "Lipoprotein lipase-mediated sequestration of long-chain polyunsaturated triacylglycerols in serum LDL from normal and hypothyroid rats," <i>Biochim. Biophys. Acta</i> 796(1) :64-71 (Oct. 1984).					
	22.	Ridgway et al., "Serum activity and hepatic secretion of lecithin: cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia," <i>J. Lipid Res.</i> 26(11) :1300-1313 (Nov. 1985).					
	23.	Scarabottolo et al., "Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver," <i>Atherosclerosis</i> 59(3) :329-333 (1986).					
	24.	Spiegelman et al., "Obesity and the regulation of energy balance," <i>Cell</i> 104(4) :531-543 (Feb. 2001).					
	25.	Sugatani et al., "The Phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase <i>UGT1A1</i> gene and regulation by the nuclear receptor CAR," <i>Hepatology</i> 33(5) :1232-1238 (2001).					
	26.	Valdemarsson et al., "Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations," <i>Acta Endocrinol.</i> 104(1) :50-56 (1983).					
	27.	Xie et al., "Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR," <i>Genes Dev.</i> 14(23) :3014-3023 (Dec. 2000).					
	28.	Yen, "Physiological and molecular basis of thyroid hormone action," <i>P.M. Physiol. Rev.</i> 81(3) :1097-1142 (Jul. 2001).					
		29.	Zelko et al., "Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes," <i>Biochem. Biophys. Res. Comm.</i> 277(1) :1-6 (Oct. 2000).				
Continue on page _____							
EXAMINER Shulamith H. Shafer				DATE CONSIDERED 02/22/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							